Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Platinum-based chemotherapy is the recommended first-line treatment for high-grade serous (HGS) epithelial ovarian cancer (EOC). However, most patients relapse because of platinum refractory/resistant disease. We aimed at assessing whether other drugs, commonly used to treat relapsed HGS-EOC and poorly active in this clinical setting, might be more effective against chemotherapy-naïve cancers. We collected couples of HGS-EOC samples from the same patients before and after neo-adjuvant platinum-based chemotherapy. Samples were propagated as Patient Derived Xenografts (PDXs) in immunocompromised mice ("xenopatients"). Xenopatients were treated in parallel with carboplatin, gemcitabine, pegylated liposomal doxorubicin (PLD) and trabectedin. PDXs derived from a naïve HSG-EOC showed responsiveness to carboplatin, trabectedin and gemcitabine. The PDXs propagated from a tumor mass of the same patient, grown after carboplatin therapy, did no longer respond to trabectedin and gemcitabine and showed heterogeneous response to carboplatin. In line, the patient experienced clinically platinum-sensitivity first and then discordant responses of different tumor sites to platinum re-challenge. Loss of PDX responsiveness to drugs was associated with 4-fold increase of NR2F2 gene expression. PDXs from another naïve tumor showed complete response to PLD, which was lost in the PDXs derived from a mass grown in the same patient after platinum-based chemotherapy. This patient showed platinum refractoriness and responded poorly to PLD as second-line treatment. PDX response to PLD was associated with high expression of TOP2A protein. PDXs demonstrated that chemotherapy-naïve HGS-EOC might display susceptibility to agents not used commonly as first line treatment. Data suggest the importance of personalizing also chemotherapy.

Original languageEnglish
Pages (from-to)26181-26191
Number of pages11
JournalOncotarget
Volume7
Issue number18
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Precision Medicine
Ovarian Neoplasms
Drug Therapy
Heterografts
trabectedin
Platinum
gemcitabine
Carboplatin
Neoplasms
Therapeutics
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Ovarian cancer
  • Patient derived xenograft

ASJC Scopus subject areas

  • Oncology

Cite this

@article{228e5dfedfce4dafbd4a11ec8f96d274,
title = "Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer",
abstract = "Platinum-based chemotherapy is the recommended first-line treatment for high-grade serous (HGS) epithelial ovarian cancer (EOC). However, most patients relapse because of platinum refractory/resistant disease. We aimed at assessing whether other drugs, commonly used to treat relapsed HGS-EOC and poorly active in this clinical setting, might be more effective against chemotherapy-na{\"i}ve cancers. We collected couples of HGS-EOC samples from the same patients before and after neo-adjuvant platinum-based chemotherapy. Samples were propagated as Patient Derived Xenografts (PDXs) in immunocompromised mice ({"}xenopatients{"}). Xenopatients were treated in parallel with carboplatin, gemcitabine, pegylated liposomal doxorubicin (PLD) and trabectedin. PDXs derived from a na{\"i}ve HSG-EOC showed responsiveness to carboplatin, trabectedin and gemcitabine. The PDXs propagated from a tumor mass of the same patient, grown after carboplatin therapy, did no longer respond to trabectedin and gemcitabine and showed heterogeneous response to carboplatin. In line, the patient experienced clinically platinum-sensitivity first and then discordant responses of different tumor sites to platinum re-challenge. Loss of PDX responsiveness to drugs was associated with 4-fold increase of NR2F2 gene expression. PDXs from another na{\"i}ve tumor showed complete response to PLD, which was lost in the PDXs derived from a mass grown in the same patient after platinum-based chemotherapy. This patient showed platinum refractoriness and responded poorly to PLD as second-line treatment. PDX response to PLD was associated with high expression of TOP2A protein. PDXs demonstrated that chemotherapy-na{\"i}ve HGS-EOC might display susceptibility to agents not used commonly as first line treatment. Data suggest the importance of personalizing also chemotherapy.",
keywords = "Chemotherapy, Ovarian cancer, Patient derived xenograft",
author = "Jessica Erriquez and Martina Olivero and Gloria Mittica and Scalzo, {Maria Stella} and Marco Vaira and {De Simone}, Michele and Riccardo Ponzone and Dionyssios Katsaros and Massimo Aglietta and Raffaele Calogero and {Di Renzo}, {Maria Flavia} and Giorgio Valabrega",
year = "2016",
month = "5",
day = "1",
doi = "10.18632/oncotarget.8325",
language = "English",
volume = "7",
pages = "26181--26191",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "18",

}

TY - JOUR

T1 - Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer

AU - Erriquez, Jessica

AU - Olivero, Martina

AU - Mittica, Gloria

AU - Scalzo, Maria Stella

AU - Vaira, Marco

AU - De Simone, Michele

AU - Ponzone, Riccardo

AU - Katsaros, Dionyssios

AU - Aglietta, Massimo

AU - Calogero, Raffaele

AU - Di Renzo, Maria Flavia

AU - Valabrega, Giorgio

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Platinum-based chemotherapy is the recommended first-line treatment for high-grade serous (HGS) epithelial ovarian cancer (EOC). However, most patients relapse because of platinum refractory/resistant disease. We aimed at assessing whether other drugs, commonly used to treat relapsed HGS-EOC and poorly active in this clinical setting, might be more effective against chemotherapy-naïve cancers. We collected couples of HGS-EOC samples from the same patients before and after neo-adjuvant platinum-based chemotherapy. Samples were propagated as Patient Derived Xenografts (PDXs) in immunocompromised mice ("xenopatients"). Xenopatients were treated in parallel with carboplatin, gemcitabine, pegylated liposomal doxorubicin (PLD) and trabectedin. PDXs derived from a naïve HSG-EOC showed responsiveness to carboplatin, trabectedin and gemcitabine. The PDXs propagated from a tumor mass of the same patient, grown after carboplatin therapy, did no longer respond to trabectedin and gemcitabine and showed heterogeneous response to carboplatin. In line, the patient experienced clinically platinum-sensitivity first and then discordant responses of different tumor sites to platinum re-challenge. Loss of PDX responsiveness to drugs was associated with 4-fold increase of NR2F2 gene expression. PDXs from another naïve tumor showed complete response to PLD, which was lost in the PDXs derived from a mass grown in the same patient after platinum-based chemotherapy. This patient showed platinum refractoriness and responded poorly to PLD as second-line treatment. PDX response to PLD was associated with high expression of TOP2A protein. PDXs demonstrated that chemotherapy-naïve HGS-EOC might display susceptibility to agents not used commonly as first line treatment. Data suggest the importance of personalizing also chemotherapy.

AB - Platinum-based chemotherapy is the recommended first-line treatment for high-grade serous (HGS) epithelial ovarian cancer (EOC). However, most patients relapse because of platinum refractory/resistant disease. We aimed at assessing whether other drugs, commonly used to treat relapsed HGS-EOC and poorly active in this clinical setting, might be more effective against chemotherapy-naïve cancers. We collected couples of HGS-EOC samples from the same patients before and after neo-adjuvant platinum-based chemotherapy. Samples were propagated as Patient Derived Xenografts (PDXs) in immunocompromised mice ("xenopatients"). Xenopatients were treated in parallel with carboplatin, gemcitabine, pegylated liposomal doxorubicin (PLD) and trabectedin. PDXs derived from a naïve HSG-EOC showed responsiveness to carboplatin, trabectedin and gemcitabine. The PDXs propagated from a tumor mass of the same patient, grown after carboplatin therapy, did no longer respond to trabectedin and gemcitabine and showed heterogeneous response to carboplatin. In line, the patient experienced clinically platinum-sensitivity first and then discordant responses of different tumor sites to platinum re-challenge. Loss of PDX responsiveness to drugs was associated with 4-fold increase of NR2F2 gene expression. PDXs from another naïve tumor showed complete response to PLD, which was lost in the PDXs derived from a mass grown in the same patient after platinum-based chemotherapy. This patient showed platinum refractoriness and responded poorly to PLD as second-line treatment. PDX response to PLD was associated with high expression of TOP2A protein. PDXs demonstrated that chemotherapy-naïve HGS-EOC might display susceptibility to agents not used commonly as first line treatment. Data suggest the importance of personalizing also chemotherapy.

KW - Chemotherapy

KW - Ovarian cancer

KW - Patient derived xenograft

UR - http://www.scopus.com/inward/record.url?scp=84966747211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966747211&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8325

DO - 10.18632/oncotarget.8325

M3 - Article

AN - SCOPUS:84966747211

VL - 7

SP - 26181

EP - 26191

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 18

ER -